-
I try to keep Twitter non-personal, but had to share: we were matched to adopt
just after #ASCO19, but it failed. We were crushed. Now... hubs & I are in AZ waiting to take custody of our new
baby girl!
She’s beautiful and perfect.
#adoption#wildridepic.twitter.com/ZU6UDxM4Ve – mjesto: Fairmont Scottsdale Princess
Prikaži ovu nit -
Updated risk stratification model for SMM incorporating revised IMWG diagnostic criteria - San Miguel et al.
#ASCO19 8000 http://ow.ly/mtOA30oMqpa#mmsm 2014 removal of SMM Pts at highest [ultra] risk of progression requires reassessment of current risk stratification models T1 -
It was nice to speak with my mentor
@PGrivasMDPhD at#ASCO19 about our work (published in@JournalCancer http://ow.ly/x0Cx30q2HY1 ) investigating response and survival outcomes in pts with advanced UC treated with checkpoint inhibitors@urotoday@BladderCancerUShttps://twitter.com/urotoday/status/1225102067393495041 …
-
At
#OCEProject2025 now,@ASCO's Caroline Schenkel discusses the#CancerLinq study@rschilsky presented at#ASCO19 which showed the Use of Broader Criteria for#ClinicalTrial Enrollment Would **Double** Number of Eligible Patients w#LungCancer.
https://www.asco.org/about-asco/press-center/news-releases/use-broader-criteria-clinical-trial-enrollment-would-double …pic.twitter.com/DQ6PoDcYSx
Prikaži ovu nit -
The next story we're opening up for
#WorldCancerDay
is a look into the most-discussed plenary session of #ASCO19: How a@flatironhealth hackathon team linked#Medicaid expansion with reduction in racial disparities in time to cancer treatment — https://cancerletter.com/articles/20190621_1/ …pic.twitter.com/531k00CQAY
-
Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis -
@DrDonaldHarvey et al.#ASCO19 Abstract LBA108 http://ow.ly/zFDM30oR19g#ClinicalTrials#lcsm -
Los doctores Jack West, Charu Aggarwal y Benjamin Levy se reunieron recientemente para revisar los principales puntos de discusión sobre
#CáncerDePulmón de#ASCO19. En este video, analizan el#NSCLC en etapa 4 y los nuevos objetivos (targets), específicamente METpic.twitter.com/7rV6w7bVfh
Prikaži ovu nit -
#ASCO19 Plenary re medicaid expansion used@flatironhealth to show policy benefits (indirectly helps patients). FDA expansion of palbociclib for male breast Ca often cited by#bigdata advocates. But companies $$ benefit is exponential (e.g. Roche's $1.9b acquisition of flatiron) -
A retrospective analysis of clinical outcomes among patients with infiltrative hepatocellular carcinoma (iHCC): A single institution study - Hannan et al.
@JCO_ASCO 37, 2019 (suppl;#ASCO19 Abstr e15667) http://ow.ly/uSJp30oYbR9#hpbcsm#PrecisionMedicinepic.twitter.com/VGDBdbz5ee
Prikaži ovu nit -
Oncology precision medicine for hepatobiliary and pancreatic cancer: an institutional review - Bellini et al.
@Aurora_Cancer#ASCO19 Abstr e14626 http://ow.ly/vMmE30oYc2Y#PrecisionMedicine#hpbcsm#pancsmpic.twitter.com/xcFdBz7UpY
Prikaži ovu nit -
Hopefully the final results of the Durvalumab / Galunisertib
#PancreaticCancer trial (presented at#ASCO19) will be published.Prikaži ovu nit -
#Oncologists have the highest suicide rate of any profession, driven by the unique emotional challenges they face. http://ms.spr.ly/6018Tn4N4#ASCO19 pic.twitter.com/k114rlBOtU
-
-
Thank you to
@LivingBeyondBC for capturing this moment of@itsnot_pink & I crafting our first tweet about#GRASPcancer @#ASCO19 - an idea which no doubt was inspired by others like@corrie_painter@coffeemommy@stage4kelly@JaniceC8957 and more!#BCSM#BCCWW#SABCS19https://twitter.com/itsnot_pink/status/1203451691187748867 …
-
At
#asco19, a patient,@christeeny513 walked the posters with@corrie_painter, a scientist. Corrie explained the hypotheses, experiments, & results. Christine talked about life with MBC, how different drugs affect her quality of life, what she is looking for in a treatment, 1/Prikaži ovu nit -
New
#OutspokenOncology is out w@DrChoueiri of@DanaFarber who deciphers#RCC and discusses advances. Amazing clinician, researcher, mentor, & educator took time last@ASCO#ASCO19 to speak w me. Find us on@iTunes@Spotify@SoundCloud & other outlets. https://www.journalofclinicalpathways.com/multimedia/episode-39-advances-renal-cell-carcinoma-toni-choueiri …pic.twitter.com/zC2TYfqQVv
-
Prior important
#ASCO19 presentation (#palbociclib +#exemestane +#GnRHa vs.#capecitabine) now in@TheLancetOncol: unless visceral crisis,#EndocrineTherapy should always be given before CT in HR+ HER2- metastatic#BreastCancer patients#OncoAlert#bcsmhttps://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30565-0/fulltext#.Xb1mvzaJta4.twitter … -
This is just fascinating! A new era for the treatment of KRAS mutant lung cancer. After AMG510 preliminary clinical activity on KRAS G12C presented this year at
#ASCO19, now MRTX849. The key was to tackled mutant KRAS in inactive GDP-bound state. And more to come!#LCSMhttps://twitter.com/VivekSubbiah/status/1188928197750116352 …
-
Live Tweet from the podium of
#ESMO19 YO brunch: Numbers from#ASCO19 shows Oncologist engagement way up in Twitter, but we can not neglect our advocates. It is our duty to help amplify their voice!!@oncoalert. Thank you@itsthebunkpic.twitter.com/yv9rClTkI3
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.